Debate on long-acting β agonists for asthma: they think it's all over

Brian Lipworth (Lead / Corresponding author), Sunny Jabbal

Research output: Contribution to journalLetterpeer-review

2 Citations (Scopus)
216 Downloads (Pure)


At last, we can apparently relax in the secure knowledge that long-acting β agonists (LABA) are safe to use in persistent asthma when given in combination with inhaled corticosteroid (ICS), on the basis of the US Food and Drug Administration-mandated studies1,2 with either fluticasone–salmeterol or budesonide–formoterol. These combinations showed no increase in serious asthma-related events and both reduced exacerbations compared with ICS alone. Do these results mean we can now prescribe ICS–LABA combination inhalers with impunity at step 3 and above of asthma guidelines?
Original languageEnglish
Pages (from-to)e14-e15
Number of pages2
JournalThe Lancet Respiratory Medicine
Issue number3
Early online date28 Feb 2017
Publication statusPublished - Mar 2017


  • Letter


Dive into the research topics of 'Debate on long-acting β agonists for asthma: they think it's all over'. Together they form a unique fingerprint.

Cite this